HIV Drug Resistance Mutations (DRMs) Detected by Deep Sequencing in Virologic Failure Subjects on Therapy from Hunan Province, China

Xi Chen¹*, Xiaobai Zou¹*, Jianmei He¹, Jun Zheng¹, Jennifer Chiarella², Michael J. Kozal²

¹ Hunan Provincial Center for Disease Control and Prevention, Changsha, China, ² Yale School of Medicine, New Haven, United States of America

* Chenx161@sohu.com

Abstract

Objective

Determine HIV drug resistance mutations (DRMs) prevalence at low and high levels in ART-experienced patients experiencing virologic failure (VF).

Methods

29 subjects from 18 counties in Hunan Province that experienced VF were evaluated for the prevalence of DRMs (Stanford DRMs with an algorithm value >15, include low-, intermediate and high-level resistance) by both Sanger sequencing (SS) and deep sequencing (DS) to 1% frequency levels.

Results

DS was performed on samples from 29 ART-experienced subjects; the median viral load 4.95×10^4 c/ml; 82.76% subtype CRF01_AE. 58 DRMs were detected by DS. 18 DRMs were detected by SS. Of the 58 mutations detected by DS, 40 were at levels <20% frequency (26 NNRTI, 12 NRTI and 2 PI) and the majority of these 95.00% (38/40) were not detected by standard genotyping. Of these 40 low-level DRMs, 16 (40%) were detected at frequency levels of 1–4% and 24 (60%) at levels of 5–19%. SS detected 15 of 17 (88.24%) DRMs at levels >20% that were detected by DS. The only variable associated with the detection of DRMs by DS was ART adherence (missed doses in the prior 7 days); all patients that reported missing a dose in the last 7 days had DRMs detected by DS.

Conclusions

DS of VF samples from treatment experienced subjects infected with primarily AE subtype frequently identified Stanford HIVdb NRTI and NNRTI resistance mutations with an
algorithm value 15. Low frequency level resistant variants detected by DS were frequently missed by standard genotyping in VF specimens from antiretroviral-experienced subjects.

Introduction

At the end of 2013, Hunan province which is located in south central China had a population of 68 million. Since the first case of HIV was diagnosed in Hunan in 1992, 19,661 HIV/AIDS cases have been reported through 2013 with 5,871 AIDS related deaths. The primary HIV transmission modes in this region are injection drug use (IDU) and sexual contact. By the end of 2013, 9,594 HIV positive patients were under care and receiving free Antiretroviral Therapy (ART) which is supported by the government in Hunan Province, China. Initial choices for first line antiretroviral therapy consist of triple therapy selected from Stavudine (d4T), Lamivudine (3TC), Zidovudine (AZT), Tenofovir (TDF), Efavirenz (EFV) and Nevirapine (NVP), EFV, AZT, d4T, 3TC and NVP are generically produced in China. Lopinavir/ritonavir (LPV/r) a second-line drug has not yet been widely used in Hunan Province. Epidemiological surveys have revealed that China is currently one of the countries in which a wide range of HIV-1 subtypes and CRFs are cocirculating [1]. A recent Hunan Province molecular epidemiology survey (2009–2013) revealed that 4 HIV-1 subtypes, CRF_01AE, CRF07_BC, B and C are circulating in Hunan Province with CRF_01AE being the dominant subtype (more than 80%) [2–6].

The sensitive and accurate detection of drug resistance mutations (DRMs) is very important to the proper diagnosis and treatment of HIV-infected persons. Infection with DRMs can lead to ART failure and is associated with increased mortality [7–10]. Standard HIV genotyping using Sanger sequencing (SS) methods may not detect all resistant viral variants. The SS methods in clinically approved HIV genotypic resistance assays typically can detect dominant viral variants (resistant variants level C21esi frequency) but will miss mostly low-level variants with mutations (<20%) [7–11]. Recent studies have demonstrated that some low level DRMs (> 1%) can become dominant variants rapidly under drug selected pressure and lead to virologic failure (VF) [10, 12–16]. However, these low level DRMs can be detected by more sensitive technologies like deep sequencing (DS) [17–24]. In this study, we define "low-level" DRMs as mutations detected at <20% frequency levels of the viral quasi-species by DS. There is little data on the prevalence of low level HIV variants with drug resistance mutations in non B/C HIV subtypes and very few studies investigating low-level drug-resistant variants in subjects experiencing virologic failure on first line ART in China.

The objective of this study was to determine the prevalence of Stanford HIVdb and DRMs at both low and high levels in ART-experienced VF subjects by DS and by standard HIV genotyping.

Materials and Methods

Ethics Statement

The research protocol, approved by the relevant institutional review boards or independent ethics committees was conducted in accordance with standards for the protection of patient safety and welfare and in compliance with Good Clinical Practices and the principles of the Declaration of Helsinki and its amendments. The study was conducted at two clinical sites, in Hengyang City and Changsha City Hunan Province, after it was approved by the local Ethics committee: Hunan Provincial Center for Disease Control and Prevention Human Investigative Committees/IRBs. At each site, clients receive comprehensive evaluation and ART when
indicated. According to "National Free AIDS ARV guideline" (China, 2012), all participants who receive treatment from AIDS ARV that support by Chinese government, have to perform viral load testing and genotypic testing, which will be used for this study. Verbal informed consent will be given by the doctors at the two clinical sites who are responsible for the AIDS patients, and their names will be kept on a list with the doctors' signature. The study and the verbal consent procedure were approved by a single IRB, and its name is "the Hunan Provincial Center for Disease Control and Prevention Human Investigative Committee".

Patients

The Chinese national free ARV treatment policy guidelines recommends that patients on ART should have an HIV viral load test at least once a year [25]. If the viral load is >1000 copies/ml a HIV drug resistance genotypic test (Sanger Sequencing based) should be performed. A total of 29 subjects with AIDS from 18 counties in Hunan Province were enrolled in the study. Primary inclusion criteria: 1) HIV-infected; 2) on ART more than 12 months; 3) a minimum of 18 years of age; 4) a plasma HIV RNA ≥10,000 copies/mL with any CD4+ lymphocyte count.

RNA extraction, amplification and Sanger sequencing

RNA was isolated from 140 ul of plasma using the QIAmp Viral RNA mini kit (Qiagen, Germany), in accordance with the manufacturer’s protocol, and eluted to a 60 uL suspension. Approximately 1.4x10^3 bp pol fragments (HXB2 positions 2028–3462) were amplified by nested reverse transcriptase polymerase chain reaction (nested RT-PCR) using RT-PCR kits (Takara, Dalian, China) and Taq PCR Mastermix (Tiangen, Beijing, China), the pol region including the entire protease gene and partial polymerase gene for genotyping and DRM analysis.

The results from sequencing were aligned and assembled manually into contiguous sequences using Contig Express Project, a component of the Vector NTI Suite 6 software. To determine drug-resistant mutations and amino acid polymorphisms, each sequence was analysis in the Stanford HIV Drug Resistance Database (http://hivdb.stanford.edu).

Deep sequencing (454) analysis

The viral RNA was isolated from 140 ul of plasma using the QIAmp Viral RNA mini kit (Qiagen, Germany) with 2 ug of the included polyA-RNA carrier, and were sent to Application support center (Roche Applied Science, Asia Pacific) for DS. The laboratory was given viral load information but was blinded to the standard sequencing results and clinical data. There were four primers sets that were used to amplify the HIV POL region, include protease (PR) and reverse transcriptase (RT) genes. The fusion primers containing the Roche 454 amplicon adaptor sequences, multiplex identifier (MID) tags on both forward and reverse primers. Following PCR amplification, all PCR products were purified using an AMPure XP (Agencourt) bead clean-up for twice, then quantitated using the Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen Carlsbad, CA, USA), according to the Protocol for Amplicon Sequencing of HIV RT and PR(454 Life Sciences, Roche)[26]. Then all amplicons were pooled together at equimolar ratios, for the emulsion PCR which was performed according to GS Junior emPCR amplification method manual (454-Roche, USA). After the enrichment of the emulsion PCR products, the picotiter plate (PTP) was prepared and 5.00×10^5 enriched beads were deposited into each well of PTP and pyrosequenced from both ends (forward and reverse) by GS Junior System (454 Life Sciences, Roche, Branford, CT, US).
Drug Resistance Mutation Analysis

The sequencing results were analyzed using the GS Amplicon Variant Analyzer (AVA) software (Roche). The subtype and DRMs was performed by AVA. Ultra deep sequencing was performed as described in previous studies and the level of DS variant detection has been previously reported [27–31]. For the purpose of discussion in this paper, we reported a variant detection limit of >1% as resistant variants at this level have been shown to be clinically relevant [10, 32–34]. In addition, the level of >1% was chosen as the 454 platform used in this study has demonstrated high intralaboratory and interlaboratory consistency in the detection of mutants present at a frequency between 1 and 10% in a large multicentre evaluations [35–37].

The analysis for DRMs in this study was performed using Stanford HIV Drug-Resistance Database and all mutations with a resistance score of ≥15 for any drug were considered (http://hivdb.stanford.edu) [38]. For the purpose of discussion in this paper, low-level DRMs mutations were defined as mutations detected at <20% level of the viral quasispecies, whereas high-level DRMs were those detected at ≥20%, and the statistical analysis was performed using SPSS computer software (SPSS, Version 13.0, SPSS, Inc., Chicago, IL). Findings with $P < 0.05$ were considered statistically significant.

Result

All 29 subjects had experienced virologic failure on ART with a median HIV viral load of VF of $4.95 \times 10^4$ c/ml (range: $1.41 \times 10^4$–$8.66 \times 10^5$ copies/ml). The median CD4 cell count at VF was 178 cells/mm$^3$ (range 1 to 579 cells/mm$^3$); 82.76% (24/29) of subjects were infected with HIV subtype CRF01_AE, 10.34% (3/29) B and 6.90% (2/29) were subtype C. Among these 29 subjects, 22 (75.86%) were male and 7 (24.14%) were female. HIV transmission risk factors reported: 20 subjects (68.97%) via heterosexual sex, 8 (27.59%) IDU, and 1 (3.45%) MSM. All were adults with a mean age of 41.42 years of age (range: 24 to 75).

Of the 29 subjects, 44.83% (13/29) had been treated in 2012, 24.14% (7/29) in 2011 and 31.03 (9/29) were started on ART before 2010; 44.83% (13/29) subjects were on the first line regimen NVP+3TC+AZT, 41.38% (12/29) on EFV+3TC+AZT, with 2 subjects on 3TC+AZT+LPV/r, 1 on EFV+3TC+TDF and 1 received NVP+3TC+TDF.

All 29 subjects had HIV genotyping performed by SS and DS. Of the 29 subjects, 37.93% (11/29) did not have any DRMs (algorithm value ≥15) identified by SS or DS. Of these 11 subjects, 6 were receiving NVP+3TC+AZT, 4 on EFV+3TC+AZT and 1 on 3TC+AZT+LPV/r. Eighteen of 29 (62.07%) subjects had viral variants with a DRM to any PI, N(t)RTI and/or NNRTI drug (algorithm value ≥15) at levels >0.1% by DS and/or SS. Nine subjects (31.03%) had DRMs detected by both SS and DS, and 9 (31.03%) had DRMs detected only by DS.

A total of 58 DRMs were identified in the 18 subjects by either of the two methods; 62.07% (36/58) were NNRTI mutations: K103N(8), V108I(5), G190A/E(5), Y181C/H/L(4), Y188C/H(3), P227H(3), K101E(2), A98G(1); 34.48% (20/58) were NRTI: M184V(5), T215F(3), M41L(2), K65R/N(2), D67N(2), L74V(2), V75M(2), K70R(1), K219(1); and only 3.4% (2/58) were PI mutations: LV32I and M46L (Table 1). Only 18 DRMs were detected by SS. 13 (68.42%, 13/19) NNRTI mutations: K103N(6), Y181C/V(2), G190A(2), Y188H(1), K101E(1), T215F(1); 5 NRTI mutations: M184V(3), K65R(1), D67N(1); and two PI mutation were not detected by SS. Of the DRMs detected by SS, Seventeen (94.4%) of the 18 DRMs detected by SS were also detected by DS. Fifty seven of the 58 DRMs were detected by DS. One DRM detected by SS was not detected by DS, mutation levels ranged from 16.2–100.0% (Table 1). Low-level DRMs (<20%) were detected in all 18 subjects by DS and were unrecognized in 16 subjects by SS (Table 2).
Table 1. HIV drug resistance mutations detected by standard Sanger sequencing (SS) and by Deep sequencing (DS).

| NO. | VL (COPIES/ML) | TREATMENT REGIMEN | SUBTYPE | PROTEASE (% ABUNDANCE BY DS) MUTATIONS | REVERSE TRANSCRIPTASE (% ABUNDANCE BY DS) |
|-----|----------------|-------------------|---------|---------------------------------------|----------------------------------------|
|     |                |                   |         |                                      | by SS only | by both SS and DS | by DS only |
| 1   | 26356          | NVP+TDF+3TC       | AE      | K103N (16.17%)                        | L74V (1.44%), V108I(15.16%), F227L(2.04) |
| 4   | 33645          | EFV+3TC+AZT       | B       |                                       | Y188C (2.45%)                              |
| 9   | 559474         | EFV+3TC+TDF       | B       |                                       | K103N (14.97%)                              |
| 11  | 29299          | NVP+3TC+AZT       | AE      | K65R (28.08%), D67N (34.53%), Y181C (98.77%), Y188H (100%) | M41L (15.99%), L74V (2.2%), T215F (12.28%), E138G(12.14%), A98G (18.52%), K103N (16.17%), V106M (15.16%), V108I (10%), G190A (50.1%), F227L (2.04%) |
| 12  | 75401          | EFV+3TC+AZT       | AE      |                                       | M184V (7.52%), T215Y (6.64%), Y188L (7.52%) |
| 14  | 38072          | NVP+3TC+AZT       | AE      | K103N (98.91%)                        | D67N (1.44%), V108I (1.63%), G190A (2.74%), P225H (3.92%) |
| 15  | 68852          | EFV+3TC+AZT       | AE      | M184V (26.84%), K103N (97.46%)        | G190A V75M (1.72%) |
| 18  | 393742         | NVP+3TC+AZT       | AE      | M184V (91.55%), K103N (99.22%)        | K70R (15.05%), V108I (16.43%), P225H (18.21%) |
| 19  | 440099         | NVP+3TC+AZT       | C       | M46L (2.68%)                          | K103N (88.99%)                              |
| 20  | 43792          | 3TC+AZT+LPV/r     | AE      | K103N (98.99%)                        | V108I (17.16%)                              |
| 21  | 30706          | EFV+3TC+AZT       | AE      | G190A (13.45%), K101E (99.18%)        | V108I (17.16%)                              |
| 22  | 865605         | EFV+3TC+AZT       | AE      | G190E (5.09%)                         | V108I (17.16%)                              |
| 29  | 59874          | EFV+3TC+AZT       | AE      | Y181V (42.08%)                        | M184V (9.44%), Y188H (8.71%)                |
| 30  | 370747         | NVP+3TC+AZT       | AE      | M184V (100%), T215F (87.97%), K103N (99.72%) | M41L (3.48%), V75M (29.92%), E138Q (2.36%) |

(Continued)
Of the 57 DRMs detected by DS, 17 DRMs were at levels ≥20% and 40 were low-level mutations (<20%) detected by DS: 26 were NNRTI DRMs, 12 NRTI DRMs and 2 PI DRMs; the majority of these (95.00%, 38/40) were not detected by standard SS genotyping. SS detected 15 of 17 (88.24%) DRMs at levels ≥20% that were detected by DS. Of the total 40 low-level DRMs, 16 (40%) were detected at levels 1–4% and 24 (60%) at levels of 5–19%. The low-level DRMs mutations were detected for all three major antiretroviral classes used in Hunan Province; 10 of 29 (34.48%) subjects harbored low-level DRMs that predicted resistance to 2 antiretroviral class, nine (31.03%) to one class and no one had three class resistance (Table 2).

Factors associated with the detection of DRMs are listed in Table 3. The only variable associated with the detection of DRMs was ART adherence—missed doses in the prior 7 days [25]. All patients that reported missing a dose in the last 7 days had DRMs detected by DS (Table 4). There were 9 subjects that reported missing a dose in the last 7 days and all had DRMs detected by DS with 4 having only low-level variants. The average HIV viral load for the 9 subjects with poor adherence and DRMs was 1.78×10^5 copies/ml versus the 20 subjects with good adherence was 112,867 copies/ml (P = 0.427). The average HIV viral load for the 11 subjects without DRMs and good adherence was 4.45×10^4 copies/ml whereas the 18 subjects with DRMs was 1.87×10^5 copies/ml (P < 0.05).

### Table 1. (Continued)

| NO. | VL (COPIES/ML) | TREATMENT REGIMEN | SUBTYPE | PROTEASE (% ABUNDANCE BY DS) | REVERSE TRANSCRIPTASE (% ABUNDANCE BY DS) |
|-----|----------------|-------------------|---------|------------------------------|------------------------------------------|
|     |                |                   |         | by DS only                    | by both SS and DS                         |
|     |                |                   |         | by SS only                    | by DS only                                |
| 31  | 93200          | NVP+3TC +AZT      | AE      | Y181C (1.2%)                 |                                          |
| 33  | 49500          | EFV+3TC +AZT      | B       | K65N (6.01%)                 |                                          |
| 34  | 98000          | EFV+3TC +AZT      | AE      | V106A (2.43%)                |                                          |
| 35  | 92200          | NVP+3TC +AZT      | AE      | V32I (14.02%)                | K101E (1.65%), G190A (1.39%)             |

Note. Stanford HIVdb algorithm ≥15.

doi:10.1371/journal.pone.0149215.001

| DRMs class | Low-level mutations (<20%) | High-level mutations (≥20%) |
|------------|-----------------------------|-----------------------------|
|            | SS | DS | SS | DS |
| NNRTI      | 2  | 26 | 9  | 10 |
| NRTI       | 0  | 12 | 6  | 7  |
| PI         | 0  | 2  | 0  | 0  |
| ANY        | 2  | 40 | 15 | 17 |

SS—Sanger Sequencing; DS Deep Sequencing

doi:10.1371/journal.pone.0149215.002
Discussion

The results from this study revealed that CRF01_AE is still the most common subtype in Hunan province (82.76% of patients). This finding corresponds to the data from the last Hunan Province molecular epidemiology survey (2009–2013) [2–6]. In addition to the most dominant subtype, other subtypes including B and C were found, which may indicate a more complicated and diverse trend of HIV-1 epidemiology emerging in the province. In total, ~62% of subjects experiencing VF had DRMs with a Stanford HIVdb algorithm value detected at mutation levels >1%. Of the 58 DRMs detected, NNRTI mutations were the most common (62.07%) with 11 different codon positions represented: K103N, V108I, G190A/E, Y188C/H/L, V106A/M, Y181C/V, F227L, E138G/Q, P225H, K101E, A98G. All NNRTI mutations were found in the subjects who were failing a regimen containing nevirapine (NVP) and/or efavirenz (EFV). K103N was the most common mutation identified in this study; it is a non-polymorphic mutation that causes high-level resistance to NVP (~50-fold reduced susceptibility) and EFV (~20-fold reduced susceptibility). Other NNRTI mutations, G190A/E, V106A/M, Y181C/V cause high level resistance to NVP and EFV. K101E and Y188C/H cause intermediate or high-level resistance to NVP and low level resistance to EFV; F227L is a nonpolymorphic mutation that usually occurs in combination with V106A and P225H is usually occurs in combination with K103N [39–44].

The major NRTI mutations identified in our study were M184V, T215F, M41L, K65R/N, D67N, L74V, V75M, K70R and K219E. M184V was detected in 5 subjects all of whom were on a treatment regimen containing lamivudine (3TC). M184V causes high-level resistance to 3TC and FTC and low-level resistance to d4T and ABC. T215F is a thymidine analog mutation (TAM) that causes intermediate/ high-level resistance to AZT and d4T and low-level resistance

| Table 3. Factors associated with incidence of DRMs. |
|---------------------------------------------------|
| Variable                                           | Mutation identified by DS (n = 18) | No mutations identified by DS (n = 11) | Overall(N = 29) | P      |
| Regimen                                          |                               |                                     |                  |
| NVP+3TC+AZT                                      | 7 (38.9%)                     | 6 (54.5%)                           | 13               | 0.941  |
| EFV+3TC+AZT                                      | 8 (44.4%)                     | 4 (36.4%)                           | 12               |        |
| LPV/r+3TC+AZT                                    | 1 (5.6%)                      | 1 (9.1%)                            | 2                |        |
| NVP+3TC+TDF                                      | 1 (5.6%)                      | 0                                   | 1                |        |
| EFV+3TC+TDF                                      | 1 (5.6%)                      | 0                                   | 1                |        |
| CD4 abs count(cells/mm³)                          |                               |                                     |                  |
| 0<199                                            | 9 (50.0%)                     | 6 (54.5%)                           | 15               | 1.00   |
| ≥200                                             | 9 (50.0%)                     | 5 (45.5%)                           | 14               |        |
| WHO Stage                                        |                               |                                     |                  |
| I                                                | 9 (50.0%)                     | 4 (36.4%)                           | 13               | 0.901  |
| II                                               | 4 (22.2%)                     | 3 (27.3%)                           | 7                |        |
| III                                              | 2 (11.1%)                     | 2 (18.2%)                           | 4                |        |
| IV                                               | 3 (16.7%)                     | 2 (18.2%)                           | 5                |        |
| Route of transmission                            |                               |                                     |                  |
| IDU                                              | 5 (27.8%)                     | 3 (27.3%)                           | 8                | 0.503  |
| Heterosexual                                     | 13 (72.2%)                    | 7 (63.6%)                           | 20               |        |
| MSM                                              | 0 (0.0%)                      | 1 (9.1%)                            | 1                |        |
| Recently 7 days number of doses missed            |                               |                                     |                  |
| 0                                                | 9                             | 11                                 | 20               | <0.05  |
| ≥1                                               | 9                             | 0                                  | 9                |        |

doi:10.1371/journal.pone.0149215.t003
to TDF. T215F occurs more commonly with the Type II TAMs (D67N, K70R, and/or K219E) and in this context, it affects susceptibility to TDF, ABC, and ddi less markedly than T215Y. M41L is a TAM that usually occurs with T215Y. Together, M41L and T215Y confer high-level resistance to AZT and d4T and intermediate-level resistance to TDF. However, viruses with M41L + T215Y + M184V will exhibit intermediate-level resistance to AZT and d4T and low-level resistance to TDF [40–45]. All of the RT DRMs identified by DS except K103N had been reported in another HIV drug resistance mutation DS study in Hunan province in 2013 [6].

Protease gene DS revealed that there were no DRMs causing LPV/r drug resistance. The lack of LPV/r mutations may be due to the fact that LPV/r is a second line drug and has not yet been widely used in Hunan Province during the study period. Only 2 PI mutations were
identified and both were at a low-level (<20%): V32I is a nonpolymorphic substrate-cleft mutation associated with reduced susceptibility to each PI except SQV. M46L is nonpolymorphic PI-selected mutations that reduce susceptibility to IDV, NFV, FPV, LPV and ATV when present with other mutations. M46L also reduces susceptibility to TPV. IDV, NFV, FPV, LPV and ATV were not used in Hunan province, and the presence of these variants may represent a TDR acquired in another region or country or natural polymorphisms occurring at low levels.

The only variable associated with the detection of DRMs was ART adherence—missed doses in the prior 7 days; all patients that reported missing a dose in the last 7 days had DRMs detected by DS. The lack of DRMs in patients with VF and a good adherence score requires further study.

DS allowed for the detection of greater overall drug resistance burden in subjects where 17 subjects had either DRMs detected only by DS or had additional DRMs detected by DS but not detected by SS. Our study demonstrates that low level variants harboring PI, NRTI and NNRTI DRMs are commonly unrecognized by standard SS HIV genotyping in antiretroviral-experienced subjects infected with subtype AE at time of virologic failure. DRMs at levels <20% of viral quasispecies made up 69% (40/58) of the total number of mutations detected and the vast majority (>95%) were not detected by standard SS HIV genotyping. This finding is consistent with other studies that used DS to investigated subjects infected with other subtypes experiencing VF [31, 45–46]. “It has been reported by Le and colleagues in a cohort of heavily experienced subjects failing multiple ART regimens that on average 4 additional mutations (range 1 to 10) were detected by deep sequencing compared to standard sequencing [31]. The addition of these mutations present at <20% levels occurred in 77% of subjects and conferred new resistance to at least one antiretroviral drug in 50% of subjects evaluated. Similarly, in our study, 58.6% (17/29) of patients failing ART had the mutations detected at the <20% level (Table 1). The additional mutations identified only by DS increased the resistance burden in 88% (15/17) of subjects possessing DRMs which conferred new resistance to at least one ARV.” Recent studies have demonstrated that low frequency level DRMs are clinically important, as resistant variants can grow rapidly under the selection pressure exerted by ART and lead to VF [6–13, 33] and that sensitive and accurate detection of all drug-resistant HIV strains may be very important for the proper diagnosis and treatment of HIV-infected persons.

A limitation of our study is that we had no baseline genotypic data to determine if the mutant variants pre-existed in the subjects. Further, we did not have many patients on multiple prior regimens to assess the prevalence of DRMs in subjects failing multiple regimens in China. However, the report by Le and colleagues [31] suggest that deep sequencing will identify a greater level of DRMs in heavily ART treated subjects.

In summary, our study aimed to elucidate the prevalence of Stanford HIVdb DRMs detected by DS in patients experiencing treatment failure in Hunan Province, China. ART treatment-experienced subjects from Hunan Province infected predominately with subtype AE frequently possessed low-abundance HIV variants with NRTI/NNRTI DRMs. PI mutations were rarely found and may reflect the fact that PI use is infrequent in Hunan Province. Ongoing surveillance is needed for the provinces to better understand the prevalence of resistance and how best to respond to the emergence of resistance.

Supporting Information

S1 Table. HIV drug resistance mutations detected by standard Sanger sequencing (SS) and by Deep sequencing (DS).

(DOCX)
S2 Table. Prevalence of ≥1% DRMs by Stanford HDRM.

(DOCX)

S3 Table. Factors associated with incidence of DRMs.

(DOCX)

S4 Table. DRMs by DS and Recent 7 days ART adherence.

(DOCX)

Acknowledgments

This work was supported by a grant from National Science and Technology Major Project of China (No.2012ZX1001001). We also would like to thank the Roche Application Support Center Laboratory in Shanghai (Roche Applied Science, Asia Pacific) for the 454 sequencing help. All authors contributed to the design of study, data analysis and writing of the manuscript. Deep sequencing was performed by X Chen and X Zou.

Author Contributions

Conceived and designed the experiments: XC XZ JH JZ JC MJK. Performed the experiments: XC XZ. Analyzed the data: XC XZ JH JZ JC MJK. Contributed reagents/materials/analysis tools: XC XZ JH JZ JC MJK. Wrote the paper: XC XZ JH JZ JC MJK.

References

1. Shao Y. HIV/AIDS: perspective on China. AIDS Patient Care STDS. 2001 Aug; 15(8): 431–2. PMID: 11522218

2. Chen X, Xing H, He JM, Zheng J, Zou XB, Ruan YH, et al. Study on the threshold of HIV-1 drug resistance in Hunan province. Zhonghua Liu Xing Bing Xue Za Zhi. 2008 Aug; 29(8):787–9. Chinese. PMID: 19103115

3. Zou XB, He JM, Zhang GQ, Li XZ, Peng JY, Chen X. Drug resistance analysis on AIDS patients after highly active antiretroviral therapy in Hunan province. 2010 Chin J Infect control 9(5): 305–309.

4. Chen X, Xing H, He JM, Wei M, Zheng J, Ma PF, et al. A molecular epidemiological study on HIV-1 infection in Hunan province. Practical preventive medicine 2005; 12(3): 483–485.

5. He JM, Chen X, Zheng XH, Zhong P, Zou XB, Ou QY, et al. Longitudinal survey of antiretroviral drug resistance among untreated HIV-1 infection individuals in Hunan province. Practical preventive medicine 2007; 14(4): 1260–1262.

6. Xiaobai Z, Xi C, Tian H, Williams AB, Wang H, He J, et al. Prevalence of WHO transmitted drug resistance mutations by deep sequencing in antiretroviral-naïve subjects in Hunan Province, China. PLoS One. 2014 Jun 4; 9(6):e98740. doi:10.1371/journal.pone.0098740 PMID: 24896087

7. Koziel MJ, Hullsiek KH, Macarthur RD, Berg-Wolf Mv, Peng G, Xiang Y, et al. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). The Incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naïve participants started on three different antiretroviral therapy strategies. HIV Clin Trials. 2007 Nov-Dec; 8(6):357–70. PMID:18042501

8. Gianella S, Delport W, Pacold ME, Young JA, Choi JY, Little SJ, et al. Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants. J Virol, 2011(85:): 8359–8367.

9. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adult HIV infection; 2012 recommendations of the International Antiviral Society-USA panel. JAMA, 2012 (308): 387–402.

10. Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, Baxter JD, et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naïve patients significantly impact treatment outcomes. J Infect Dis. 2009 Mar 1; 199(5):693–701. doi: 10.1086/596736 PMID: 19210162

11. Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H, et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment- experienced patients are missed by standard genotype analysis. J Clin Microbiol. 2005 (43:): 406–413.
12. Johnson JA, Li JF, Wei X, Lipscomb J, Irbeck D, Craig C, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med. 2008 Jul 29; 5(7):e158. doi: 10.1371/journal.pmed.0050158 PMID: 18666824

13. Cozzi-Lepri A, Noguera-Julian M, Di Giallonardo F, Schuurman R, Dämmer M, Aitken S, et al; Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing. J Antimicrob Chemother. 2014 Oct 21.

14. Svarovskaia ES, Margot NA, Bae AS, Waters JM, Goodman D, Zhong L, et al. Low-level K65R mutants in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine. J Acquir Immune Defic Syndr. 2007 Oct 1; 46(2):174–80. PMID: 17667333

15. Palmer S, Boltz V, Maidaressi F, Kearney M, Halvas EK, Rock D, et al. Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS. 2006 Mar 21; 20(5):701–10. PMID: 16514300

16. Halvas EK, Wiegand A, Boltz VF, Kearney M, Nisley D, Wantman M, et al. Low frequency NNRTI-resistant variants contribute to failure of efavirenz-containing regimens in Treatment-Experienced Patients. J Infect Dis. 2010 Mar 20; 210(5):672–80. doi: 10.1086/650542 PMID: 20102272

17. Barzon L, Lavezzo E, Milletto V, Toppo S, Palu’ G. Applications of next-generation sequencing technologies to diagnostic virology. Int. J Mol. Sci. 2011, (12):7861–7884.

18. Dunn DT, Coughlin K, Cane PA. Genotypic resistance testing in routine clinical care. Curr. Opin. HIV AIDS. (2011). 6:251–7. PMID: 21646877

19. Metzner KJ, Gillieri SG, Knoepfel SA, Rauch P, Burgisser P, Yerly S, et al. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clin Infect Dis. 2009(48):239–247.

20. Latillaide M, Chiarella J, Yang R, Schnittman S, Wirtz V, Uy J, et al. Prevalence and clinical significance of HIV drug resistance mutations by ultradeep sequencing in antiretroviral-naive subjects in the CASTLE study. PLoS One. 2010(5):e10952.

21. Fisher R, van Zyl GU, Travers SA, Kosakovsky Pond SL, Engelbrech S, Murell B, et al. Deep sequencing reveals minor protease resistance mutations in patients failing a protease inhibitor regimen. J. Virol. 2012 (86):6231–7.

22. Vandenbroucke I, Van Marck H, Verhasselt P, Thys K, Mostmans W, Dumont S, et al. Minor variant detection in amplicons using 454 massive parallel pyrosequencing: experiences and considerations for successful applications. Biotechniques, 2011(51):167–177.

23. Palmer S, Boltz V, Maidaressi F, Kearney M, Halvas EK, Rock D, et al. Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS. 2006 Mar 21; 20(5):701–10. PMID: 16514300

24. Roquebert B, Malet I, Wirden M, Tubiana R, Valantin MA, Simon A, et al. Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors. AIDS. 2006 Jan 9; 20(2):287–9.

25. Chinese center for disease control and prevention. National Free AIDS ARV guideline, 2012 (Third edition), (Chinese).

26. 454 Life Sciences, Protocol for Amplicon Sequencing of HIV RT and PR.

27. Avidor B, Girshengorn S, Matus N, Talio H, Achnsanov S, Zeldis I, et al. Evaluation of a Bench-Top HIV Ultra-Deep Pyrosequencing Drug-Resistance Assay in the Clinical Laboratory. J Clin Microbiol, 2011, (51):880–886.

28. Hedskog C, Mild M, Jernberg J, Shenwood E, Pratt G, Leitner T, et al. Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing. Plos One. 2010 (5):e11345.

29. Mitsuya Y, Varghese V, Wang C, Liu TF, Holmes SP, Jayakumar P, et al. Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations. J Virol. 2008 Nov; 82(21):10747–55. doi: 10.1128/JVI.01827-07 Epub 2008 Aug 20. PMID: 18715933

30. Codoner FM, Pou C, Thielen A, Garcia F, Delgado R, Dalmau D, et al. Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-infected subjects. PLoS One, 2011 (6):e19461.

31. Le T, Chiarella J, Simen BB, Hanczarak B, Egholm M, Landry ML, et al. Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. PLoS One. 2009 Jun 29; 4(6):e6079. doi: 10.1371/journal.pone.0006079 PMID: 19562031;

32. Latillaide M, Chiarella J, Yang R, DeGrosky M, Uy J, Seekins D, et al. Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing. PLoS One, 2012 (7):e30118.
33. Li JZ, Paredes R, Ribaudo HJ, Kozal MJ, Svarovskaia ES, Johnson JA, et al. Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure. J Infect Dis. 2013 Mar 15; 207(6):893–7. doi: 10.1093/infdis/jis925 PMID: 23264671

34. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, Kozal MJ, et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA. 2011 Apr 6; 305(13):1327–35. doi: 10.1001/jama.2011.375 PMID: 21467286

35. Simen BB, Braverman MS, Abbate I, Aerssens J, Bidet Y, Bouchez O, et al. An international multicenter study on HIV-1 drug resistance testing by 454 ultra-deep pyrosequencing. Journal of virological methods. 2014; 204:31–7. PMID: 24731928 doi: 10.1016/j.jviromet.2014.04.007

36. Chabria S, Gupta S, Kozal MJ. Deep Sequencing of HIV: clinical and research applications. Annual Review of Genomics and Human Genetics. Annu Rev Genomics Hum Genet. 2014; 15:295–325. PMID: 24821496 doi: 10.1146/annurev-genom-091212-153406

37. Geretti AM, Paredes R, Kozal MJ. Transmission of HIV drug resistance: lessons from sensitive screening assays. Current Opinion in Infectious Diseases, Curr Opin Infect Dis. 2015 Feb; 28(1):23–30. PMID: 25501541

38. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One. 2009; 4(3):e4724. doi: 10.1371/journal.pone.0004724 PMID: 19266092

39. Metzner KJ, Rauch P, Braun P, Knechten H, Ehret R, Kom K, et al. Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naive patients. J Clin Virol. 2011(50): 156–161.

40. Halvas EK, Wiegand A, Boltz VF, Kearney M, Nissley D, Wantman M, et al. Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment-experienced patients. J Infect Dis, 2010 (201): 672–680.

41. Santos AF, Abecasis AB, Vandamme AM, Camacho RJ, Soares MA. Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G. J Antimicrob Chemother. 2009 Mar, 63(3):593–9. doi:10.1093/jac/dkn526 PMID: 19136678

42. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer R, et al. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 2011 (19): 156–164.

43. Lecossier D, Shulman NS, Morand-Joubert L, Shafer RW, Joly V, Zolopa AR, et al. Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. J Acquir Immune Defic Syndr. 2005 Jan 1; 38(1):37–42. PMID: 15608522

44. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Kozal MJ, Hullsiekh KH, et al. Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure. AIDS, 2012 (26): 185–192.

45. Pou C, Nogueira-Julian M, Pérez-Alvarez S, García F, Delgado R, Dalmau D, et al. Improved prediction of salvage antiretroviral therapy outcomes using ultrasensitive HIV-1 drug resistance testing. Clin Infect Dis. 2014 Aug 15; 59(4):578–88. D

46. Vandenhende MA, Bellocave P, Recordon-Pinson P, Reigadas S, Bidet Y, Bruyand M, et al. Prevalence and evolution of low frequency HIV drug resistance mutations detected by ultra deep sequencing in patients experiencing first line antiretroviral therapy failure. PLoS One. 2014 Jan 27; 9(1):e86771. doi: 10.1371/journal.pone.0086771 PMID: 24475178